Get the Stockscreener App
8.06
0.75%
0.06
Iteos Therapeutics Inc stock is traded at $8.06, with a volume of 282.61K.
It is up +0.75% in the last 24 hours and up +8.63% over the past month.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
See More
Previous Close:
$8.00
Open:
$8.1
24h Volume:
282.61K
Relative Volume:
0.55
Market Cap:
$294.46M
Revenue:
$127.70M
Net Income/Loss:
$-108.14M
P/E Ratio:
-2.6867
EPS:
-3
Net Cash Flow:
$-117.52M
1W Performance:
+5.22%
1M Performance:
+8.63%
6M Performance:
-48.76%
1Y Performance:
-23.60%
1-Day Range:
$7.96
$8.31
1-Week Range:
$7.61
$8.31
52-Week Range:
$7.09
$18.75
Iteos Therapeutics Inc Stock (ITOS) Company Profile
Name
Iteos Therapeutics Inc
Sector
Industry
Phone
857-204-4583
Address
321 ARSENAL STREET, WATERTOWN
Compare ITOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ITOS
Iteos Therapeutics Inc
|
8.06 | 294.46M | 127.70M | -108.14M | -117.52M | -3.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Iteos Therapeutics Inc Stock (ITOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-24 | Initiated | Wells Fargo | Overweight |
| May-05-21 | Initiated | H.C. Wainwright | Buy |
| Oct-08-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | SVB Leerink | Outperform |
| Aug-18-20 | Initiated | Wedbush | Outperform |
View All
Iteos Therapeutics Inc Stock (ITOS) Latest News
JPMorgan Chase & Co. Purchases 5,368 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
HC Wainwright Reaffirms “Buy” Rating for iTeos Therapeutics (NASDAQ:ITOS) - Defense World
Short Interest in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Declines By 21.1% - MarketBeat
All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy - MSN
iTeos Therapeutics' (ITOS) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
(ITOS) On The My Stocks Page - Stock Traders Daily
Barclays PLC Has $1.16 Million Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Invivyd (NASDAQ:IVVD) vs. iTeos Therapeutics (NASDAQ:ITOS) Head-To-Head Comparison - Defense World
Iteos Therapeutics advances anti-TREM2 monoclonal antibody toward IND filing - BioWorld Online
iTeos Therapeutics Plans 2025 Data Presentation on Therapies - TipRanks
iTeos Therapeutics to raise $120 million via registered direct offering - MSN
Wedbush Reaffirms Outperform Rating for iTeos Therapeutics (NASDAQ:ITOS) - Defense World
iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Informazione.it
iTeos annonce ses priorités stratégiques et ses étapes clés prévues pour 2025 - GlobeNewswire Inc.
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones - GlobeNewswire
iTeos Therapeutics' (ITOS) "Outperform" Rating Reaffirmed at Wedbush - MarketBeat
iTeos Unveils Ambitious 2025 Cancer Drug Pipeline: Multiple Phase 2 Readouts, $684M Cash Runway - StockTitan
iTeos Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Trading (ITOS) With Integrated Risk Controls - Stock Traders Daily
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Bought by Geode Capital Management LLC - Defense World
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Holdings Trimmed by Franklin Resources Inc. - Defense World
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Stock Holdings Lessened by Barclays PLC - Defense World
Reviewing Calidi Biotherapeutics (NYSE:CLDI) & iTeos Therapeutics (NASDAQ:ITOS) - Defense World
State Street Corp Increases Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
State Street Corp Increases Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - MarketBeat
Trend Tracker for (ITOS) - Stock Traders Daily
Wells Fargo & Company Has Lowered Expectations for iTeos Therapeutics (NASDAQ:ITOS) Stock Price - Defense World
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
iTeos Therapeutics price target lowered to $19 from $31 at Wells Fargo - Yahoo Finance
iTeos Therapeutics (NASDAQ:ITOS) Price Target Cut to $19.00 by Analysts at Wells Fargo & Company - MarketBeat
Inupadenant “deprioritised” by iTeos in favour of pipeline TIGIT therapy - MSN
Merck, iTeos dropping assets, Viridian data — BioCentury’s Clinical Report - BioCentury
iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024 - Seeking Alpha
Merck & Co. Calls Time On Flop TIGIT And LAG-3 Programs - News & Insights
Charles Schwab Investment Management Inc. Buys 8,397 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
iTeos Therapeutics’ (ITOS) Buy Rating Reiterated at HC Wainwright - Defense World
Wedbush Reaffirms “Outperform” Rating for iTeos Therapeutics (NASDAQ:ITOS) - Defense World
iTeos Therapeutics (NASDAQ:ITOS) Earns Buy Rating from HC Wainwright - MarketBeat
Iteos Therapeutics stock hits 52-week low at $7.52 - Investing.com India
Cancer Pipelines Shrink as Incyte, iTeos Cut Candidates Following Disappointing Data - BioSpace
Inupadenant shows promise in NSCLC Phase 2 trial results - Investing.com
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial - GlobeNewswire
ITeos Therapeutics, Inc. Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress - Marketscreener.com
Intech Investment Management LLC Invests $154,000 in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
RA Capital Management L.P. Cuts Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - MarketBeat
(ITOS) Technical Data - Stock Traders Daily
Quest Partners LLC Has $113,000 Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Vestal Point Capital LP Has $10.47 Million Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - MarketBeat
Victory Capital Management Inc. Lowers Stock Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Bought by Algert Global LLC - MarketBeat
iTeos to Participate in Upcoming Investor Conferences - GlobeNewswire
Iteos Therapeutics Inc Stock (ITOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):